- Home
- CSTL
as of 02-05-2026 3:56pm EST
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 1.2B | IPO Year: | 2019 |
| Target Price: | $46.67 | AVG Volume (30 days): | 407.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.59 - $44.28 | Next Earning Date: | 02-26-2026 |
| Revenue: | $343,530,000 | Revenue Growth: | 10.15% |
| Revenue Growth (this year): | 2.88% | Revenue Growth (next year): | -0.99% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | 25.4M | FCF Growth: | -26.52% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
Pres. & Chief Exec. Officer
Avg Cost/Share
$38.22
Shares
817
Total Value
$31,035.32
Owned After
83,869
Pres. & Chief Exec. Officer
Avg Cost/Share
$39.91
Shares
3,200
Total Value
$127,721.60
Owned After
83,869
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$40.01
Shares
4,017
Total Value
$160,732.22
Owned After
83,869
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$40.10
Shares
1,339
Total Value
$53,688.54
Owned After
83,869
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$38.09
Shares
2,678
Total Value
$102,005.02
Owned After
83,869
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$40.35
Shares
830
Total Value
$33,490.50
Owned After
83,869
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$38.55
Shares
12,821
Total Value
$494,300.83
Owned After
83,869
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$39.03
Shares
19,525
Total Value
$757,098.86
Owned After
83,869
Chief Commercial Officer
Avg Cost/Share
$37.48
Shares
13,200
Total Value
$494,736.00
Owned After
86,825
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$37.45
Shares
4,496
Total Value
$168,375.20
Owned After
50,326
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Feb 4, 2026 | Sell | $38.22 | 817 | $31,035.32 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Feb 3, 2026 | Sell | $39.91 | 3,200 | $127,721.60 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 20, 2026 | Sell | $40.01 | 4,017 | $160,732.22 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 6, 2026 | Sell | $40.10 | 1,339 | $53,688.54 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 5, 2026 | Sell | $38.09 | 2,678 | $102,005.02 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 22, 2025 | Sell | $40.35 | 830 | $33,490.50 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 16, 2025 | Sell | $38.55 | 12,821 | $494,300.83 | 83,869 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 15, 2025 | Sell | $39.03 | 19,525 | $757,098.86 | 83,869 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Dec 11, 2025 | Sell | $37.48 | 13,200 | $494,736.00 | 86,825 | |
| Stokes Frank | CSTL | Chief Financial Officer | Dec 11, 2025 | Sell | $37.45 | 4,496 | $168,375.20 | 50,326 |
Compare CSTL vs Leading Stocks
See how CSTL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.